drugset / Trial / NCT04175808
Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
RandomizedCrossoverTriple-blindTreatment
Summary
The primary objective of this study is to assess the effect of a single therapeutic (50 mg) oral dose of omecamtiv mecarbil (OM) on the QT interval / QT interval corrected for heart rate (QTc), relative to placebo, in healthy adults. The QT interval is the section on an electrocardiogram (ECG) that represents the time it takes for the electrical system to fire an impulse through the ventricles and then recharge, or the time it takes for the heart muscle to contract and then recover.
Timeline
- Start
- 2019-11-14
- Primary completion
- 2020-03-04
- Completion
- 2020-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | Omecamtiv Mecarbil | Small molecule | 25 mg | Oral |
| Subject | Omecamtiv Mecarbil | Small molecule | 50 mg | Oral |
Indications
No indication recorded.